Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders.

M. R. Liebowitz, Eric Hollander, F. Schneier, R. Campeas, L. Welkowitz, J. Hatterer, B. Fallon

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

In addition to being effective in depressive disorders, monoamine oxidase inhibitors (MAOIs) have been shown to be effective in controlled studies of patient with panic disorder with agoraphobia, social phobia, atypical depression or mixed anxiety and depression, bulimia, posttraumatic stress disorder (PTSD) and borderline personality disorder. Uncontrolled case reports have noted MAOI efficacy in obsessive-compulsive disorder (OCD), trichotillomania, dysmorphophobia and avoidant personality disorder. Reversible inhibitors of MAO-A (RIMAs) appear safer than the classical irreversible MAOIs since they have less potential to increase blood pressure. They have not been studied as yet, however, in most of the conditions responsive to MAOIs. If RIMAs are found effective in these disorders, they would probably achieve wider use than MAOIs because they are safer and tend to cause fewer side effects.

Original languageEnglish (US)
Pages (from-to)29-34
Number of pages6
JournalActa Psychiatrica Scandinavica, Supplement
Volume360
StatePublished - 1990
Externally publishedYes

Fingerprint

Monoamine Oxidase Inhibitors
Psychiatry
Monoamine Oxidase
Trichotillomania
Depression
Agoraphobia
Borderline Personality Disorder
Bulimia
Panic Disorder
Obsessive-Compulsive Disorder
Personality Disorders
Depressive Disorder
Post-Traumatic Stress Disorders
Anxiety
Blood Pressure

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Liebowitz, M. R., Hollander, E., Schneier, F., Campeas, R., Welkowitz, L., Hatterer, J., & Fallon, B. (1990). Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders. Acta Psychiatrica Scandinavica, Supplement, 360, 29-34.

Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders. / Liebowitz, M. R.; Hollander, Eric; Schneier, F.; Campeas, R.; Welkowitz, L.; Hatterer, J.; Fallon, B.

In: Acta Psychiatrica Scandinavica, Supplement, Vol. 360, 1990, p. 29-34.

Research output: Contribution to journalArticle

Liebowitz, MR, Hollander, E, Schneier, F, Campeas, R, Welkowitz, L, Hatterer, J & Fallon, B 1990, 'Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders.', Acta Psychiatrica Scandinavica, Supplement, vol. 360, pp. 29-34.
Liebowitz, M. R. ; Hollander, Eric ; Schneier, F. ; Campeas, R. ; Welkowitz, L. ; Hatterer, J. ; Fallon, B. / Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders. In: Acta Psychiatrica Scandinavica, Supplement. 1990 ; Vol. 360. pp. 29-34.
@article{c19133964fab4adf95b9f992b691dc61,
title = "Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders.",
abstract = "In addition to being effective in depressive disorders, monoamine oxidase inhibitors (MAOIs) have been shown to be effective in controlled studies of patient with panic disorder with agoraphobia, social phobia, atypical depression or mixed anxiety and depression, bulimia, posttraumatic stress disorder (PTSD) and borderline personality disorder. Uncontrolled case reports have noted MAOI efficacy in obsessive-compulsive disorder (OCD), trichotillomania, dysmorphophobia and avoidant personality disorder. Reversible inhibitors of MAO-A (RIMAs) appear safer than the classical irreversible MAOIs since they have less potential to increase blood pressure. They have not been studied as yet, however, in most of the conditions responsive to MAOIs. If RIMAs are found effective in these disorders, they would probably achieve wider use than MAOIs because they are safer and tend to cause fewer side effects.",
author = "Liebowitz, {M. R.} and Eric Hollander and F. Schneier and R. Campeas and L. Welkowitz and J. Hatterer and B. Fallon",
year = "1990",
language = "English (US)",
volume = "360",
pages = "29--34",
journal = "Acta Psychiatrica Scandinavica, Supplement",
issn = "0065-1591",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders.

AU - Liebowitz, M. R.

AU - Hollander, Eric

AU - Schneier, F.

AU - Campeas, R.

AU - Welkowitz, L.

AU - Hatterer, J.

AU - Fallon, B.

PY - 1990

Y1 - 1990

N2 - In addition to being effective in depressive disorders, monoamine oxidase inhibitors (MAOIs) have been shown to be effective in controlled studies of patient with panic disorder with agoraphobia, social phobia, atypical depression or mixed anxiety and depression, bulimia, posttraumatic stress disorder (PTSD) and borderline personality disorder. Uncontrolled case reports have noted MAOI efficacy in obsessive-compulsive disorder (OCD), trichotillomania, dysmorphophobia and avoidant personality disorder. Reversible inhibitors of MAO-A (RIMAs) appear safer than the classical irreversible MAOIs since they have less potential to increase blood pressure. They have not been studied as yet, however, in most of the conditions responsive to MAOIs. If RIMAs are found effective in these disorders, they would probably achieve wider use than MAOIs because they are safer and tend to cause fewer side effects.

AB - In addition to being effective in depressive disorders, monoamine oxidase inhibitors (MAOIs) have been shown to be effective in controlled studies of patient with panic disorder with agoraphobia, social phobia, atypical depression or mixed anxiety and depression, bulimia, posttraumatic stress disorder (PTSD) and borderline personality disorder. Uncontrolled case reports have noted MAOI efficacy in obsessive-compulsive disorder (OCD), trichotillomania, dysmorphophobia and avoidant personality disorder. Reversible inhibitors of MAO-A (RIMAs) appear safer than the classical irreversible MAOIs since they have less potential to increase blood pressure. They have not been studied as yet, however, in most of the conditions responsive to MAOIs. If RIMAs are found effective in these disorders, they would probably achieve wider use than MAOIs because they are safer and tend to cause fewer side effects.

UR - http://www.scopus.com/inward/record.url?scp=0025616984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025616984&partnerID=8YFLogxK

M3 - Article

VL - 360

SP - 29

EP - 34

JO - Acta Psychiatrica Scandinavica, Supplement

JF - Acta Psychiatrica Scandinavica, Supplement

SN - 0065-1591

ER -